Aims: To assess the safety and efficacy of omarigliptin in subjects with type 2 diabetes mellitus (T2DM) and chronic renal impairment (RI).
impairment (RI), especially those with an eGFR <45 mL/min/1.73 m 2 or end-stage renal disease (ESRD) on dialysis, is more restricted than for patients with T2DM with normal renal function or mild RI, despite recent recommendations that broaden the use of metformin in this population. [5] [6] [7] Over the past decade, dipeptidyl peptidase-4 (DPP-4) inhibitors have become an established therapy for the treatment T2DM 8, 9 and are among the treatment options available for patients with T2DM and chronic RI. 5 Omarigliptin (MK-3102) is a selective, oral DPP-4 inhibitor with a half-life that enables once-weekly dosing that is primarily eliminated by renal excretion. 10 A once-weekly oral antihyperglycaemic agent (AHA) has the potential to provide patients with T2DM an additional option for managing their glycaemic control as part of a patientcentred approach. Omarigliptin has previously been demonstrated to have efficacy comparable to sitagliptin, a marketed daily DPP-4 inhibitor, 11, 12 and is approved in Japan.
Herein, we report the results of a global, double-blind, randomised, parallel-group Phase 3 clinical trial, which assessed the efficacy and safety of omarigliptin administered once-weekly (q.w.) in subjects with moderate and severe RI and ESRD on dialysis.
| MATERIALS AND METHODS

| Subjects
Eligible patients for the study were male or female ≥30 years of age with T2DM and moderate RI (eGFR ≥30 to <60 mL/min/1.73 m 2 ) or severe RI (eGFR <30 mL/min/1.73 m 2 ), as determined by the modification of diet in renal disease (MDRD) formula, 13 or ESRD on dialysis for at least 6 months. Eligible patients were either (1) not on an AHA (naïve or off therapy for ≥12 weeks) with glycated haemoglobin (HbA1c) ≥7.0% and ≤10.0%; (2) on a single oral AHA or lowdose dual oral combination AHA (ie, at ≤50% of maximum labelled dose of each agent) with an HbA1c of ≥6.5% and ≤9.0%; or (3) on a stable insulin regimen, at a dose of at least 15 U/d, for ≥10 weeks, with no oral AHA and HbA1c ≥7.5% and ≤10.0% and fasting plasma glucose (FPG) >7.22 mmol/L. Subjects on oral AHA therapy had their medication discontinued ("washed-off"). Subjects had a fasting finger-stick glucose >7.22 mmol/L and <14.43 mmol/L at randomisation. Subjects who entered the trial on insulin monotherapy at screening were to remain on a stable dose of insulin throughout the remainder of the trial unless glycaemic rescue criteria were met (see below). A stable insulin regimen was defined as all daily insulin doses within ±10% of the subject's usual administered daily dose.
Subjects could be receiving premixed, intermediate-acting or longacting insulin (premeal short-acting or rapid-acting insulins were not allowed).
Patients were excluded from the study if they had type 1 diabetes, a history of ketoacidosis, a C-peptide level <0.7 ng/mL, active liver disease, significant cardiovascular disease, a haematological disorder or a history of malignancy, or had been treated with any incretin mimetic or thiazolidinedione within the prior 12 weeks of screening, or with omarigliptin at any time prior to signing informed consent.
Laboratory exclusion criteria included alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times the upper limit of normal (ULN), triglycerides >600 mg/dL or thyroid-stimulating hormone outside the central laboratory normal range.
| Study design
This was a randomised, placebo-controlled, parallel-group, double-blind, multicentre study ( Figure S1 ) conducted at 109 centres in Australia (4), Canada (3), Croatia (6), Czech Republic (5), Georgia (6), Hong Kong (5), Hungary (6), Israel (4), Malaysia (9), Philippines (3), Poland (7), Russia (5), Serbia (3), South Africa (4), Spain (8), the United Kingdom (4) and the United States (27). Study duration was up to 69 weeks, including a 1-week screening period, an 8-week "wash-off" period (for patients on oral AHA at screening), a 2-week single-blind placebo run-in period, a 54-week double-blind treatment period consisting of a 24-week placebocontrolled period (Phase A) and a 30-week active-controlled period (Phase B) and a post-trial phone follow-up 28 days after final dose.
Subjects were randomised to omarigliptin or matching placebo in a 1:1 ratio. Randomisation was stratified based on renal status, medical history of cardiovascular disease or heart failure and treatment with insulin at screening. Subjects with moderate RI received omarigliptin 25 mg or matching placebo q.w. Subjects with severe RI or with ESRD on dialysis received omarigliptin 12.5 mg or matching placebo q.w.
During Phase B, subjects receiving placebo during Phase A continued to receive omarigliptin placebo; those who were not on insulin were treated with blinded glipizide at a starting dose of 2.5 mg once daily and electively titrated, based on glycaemic control, up to a maximum of 20 mg/d. During Phase B, subjects receiving either omarigliptin or placebo and who were on insulin during Phase A continued to receive omarigliptin or placebo and did not receive blinded glipizide/ glipizide-matching placebo. Subjects receiving omarigliptin who were not on insulin during Phase A received glipizide-matching placebo.
Subjects not meeting progressively stricter prespecified glycaemic control criteria postrandomisation were rescued (see Figure S1 ). 
| Study evaluations
The primary objectives of Phase A of this study were assessment of 
| Efficacy end-points
Efficacy end-points were changes from baseline in HbA1c and FPG and percentages of subjects at HbA1c goal of <7.0%.
| Safety end-points
Safety assessment included collection of AEs, physical examination (including vital signs), laboratory blood chemistry (including ALT, AST, total bilirubin, creatine kinase and alkaline phosphatase), lipid panel, haematology, urinalysis and electrocardiogram. In addition, at the request of several European countries, measurements of serum amylase and lipase were instituted after the study was initiated; therefore, not all subjects had baseline values. Renal function was assessed by measuring eGFR (MDRD formula 13 ). A standard questionnaire was provided to subjects to collect hypoglycaemia information.
Potential patients with pancreatitis (events assessed by the investigator as possibly being pancreatitis or events meeting prespecified event terms suggestive of pancreatitis) and prespecified hypersensitivity AEs (anaphylactic reaction, angiooedema, asthma-bronchospasm, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms) were evaluated in a blinded manner by external clinical adjudication committees. 
| Population pharmacokinetics
| Statistical methods
For efficacy analyses, the primary population included all randomised subjects who received at least one dose of study treatment and had a baseline or a postrandomisation measurement. Data acquired after the initiation of rescue therapy was treated as missing to avoid the confounding influence of rescue therapy.
Analysis of the primary efficacy end-point (change from baseline in HbA1c) used a longitudinal data analysis (LDA) model 14 including terms for treatment, RI stratum, baseline treatment with insulin stratum, time, the interaction of time by treatment, the interaction of time by RI stratum and the interaction of time by baseline treatment with insulin stratum, with a constraint that true mean at baseline is common to all treatment groups (which is valid as a result of randomisation). The primary hypothesis regarding the superiority of omarigliptin compared with placebo in decreasing HbA1c was assessed using the estimated treatment difference from the LDA model. Change from baseline in FPG was analysed using the same LDA model, substituting the appropriate baseline efficacy measurement for HbA1c.
For the analysis of percentages of individuals at the HbA1c goal of <7.0% at Week 24, the LDA model described above was used to impute missing HbA1c data. Ten sets of imputations of each missing value were constructed from the LDA model. Observed data were not imputed. After imputations, all subjects were categorised as at or not at the goal at Week 24. The estimated proportions of subjects at the goal from the 10 imputed datasets were combined using standard multiple imputation techniques proposed by Rubin 15 to yield an overall estimate of response rate and associated variance for each group.
The estimated response rates and adjusted effective sample sizes were used to obtain the confidence interval (CI) for between-group rate difference by the method of Miettinen and Nurminen 16 stratified by RI stratum and baseline treatment with insulin stratum.
Efficacy end-points at Week 54 were summarised. No betweengroup comparisons were prespecified or intended for Week 54, since treatments were not concurrently initiated, and the placebo group switched to glipizide was no longer the intact group randomised at the beginning of the trial. Statistical models and analysis populations for Week 54 were analogous to those at Week 24.
For safety analyses, the population of all randomised subjects who received at least one dose of study treatment was used. All safety endpoints were analysed for the time frame consisting of the Treatment Period +28 days. The primary safety analysis excluded data after rescue to avoid the confounding effect of rescue medication. AEs of symptomatic hypoglycaemia were prespecified as events of interest and point estimates with P-values and 95% CI for between-treatment differences in the percentages of subjects with symptomatic hypoglycaemia events were calculated using the method of Miettinen and Nurminen, 16 with RI stratum and baseline insulin stratum as stratification factors. For body weight and eGFR, change from baseline was analysed using the LDA method described above for HbA1c, substituting the appropriate baseline value for the HbA1c.
The trial targeted the enrolment of 100 subjects (50 subjects/arm) with moderate RI; 60 subjects (30 subjects/arm) with severe RI; and 50 subjects (25 subjects/arm) with ESRD on dialysis. Subjects with moderate RI were to be enrolled so that at least 50% of subjects had an eGFR from ≥30 to ≤45 mL/min/1.73 m 2 . Using a standard deviation (SD) of 1.0% and factoring for expected missing data, 105 randomised subjects per treatment group was calculated to provide 90% power to detect a true difference of 0.47% in the mean change from baseline in HbA1c (2-sided test, α=0.05).
For the assessment of safety, two treatment periods are described below: the placebo-controlled period (Phase A) and the combined 54-week treatment period (Phase A and B).
| RESULTS
| Patient disposition and characteristics
A total of 644 patients were screened and 431 were excluded during screening ( Figure S2 ). The most common reason for not being Baseline demographics and efficacy parameters were generally balanced between the randomised treatment groups ( 
| Efficacy results
| Phase A (24-week placebo-controlled period)
From a mean baseline in HbA1c of 8.4% in the omarigliptin group and 8.3% in the placebo group, the LS mean (95% CI) for the change from baseline at Week 24 in HbA1c was −0.77% (−1.00 to −0.54) in the omarigliptin group and −0.44% (−0.67 to −0.21) in the placebo group with a between-group difference of −0.33% (−0.63 to −0.02); P=0.035 (Table 2 ). The reduction in HbA1c from baseline in the omarigliptin group was generally consistent across subgroups (baseline HbA1c, age, sex, BMI, race, ethnicity, duration of diabetes, geographical region, renal stratum and insulin at screening, data not shown).
However, there was a smaller between-group difference in HbA1c in subjects using insulin (Table S1 ).
Treatment with omarigliptin led to comparable reductions in
HbA1c from baseline across renal strata, but the between-group differences across strata were affected by unusually large placebo reductions in the severe RI and ESRD strata ( Table 2 ).
The estimated percentage (95% CI) of subjects at the HbA1c target of <7.0% was 27.2% ( (Table 2) .
A post hoc analysis was performed in the moderate RI stratum, subdividing it into two subgroups: eGFR ≥45-<60 mL/min/1.73 m 2 and eGFR ≥30-<45 mL/min/1.73 m 2 (Table S2) . Although the number of subjects in these subgroups was limited, there was no attenuation of efficacy observed in the omarigliptin group in these two subgroups.
From a mean baseline HbA1c of 8.6% in the eGFR ≥45-<60 mL/ min/1.73 m 2 subgroup, the mean change from baseline in HbA1c was −0.68% (n=18) and from a mean baseline HbA1c of 8.2% in the eGFR ≥30-<45 mL/min/1.73 m 2 subgroup, the mean change from baseline in HbA1C was −0.72% (n=35).
| Phase A and Phase B (54-week treatment period)
The LS means (95% CIs) for the changes from baseline at Week 54 ( Table S3 ). The profile of change in HbA1c over time is shown in Figure 1A . Twenty-four of the 97 subjects in the placebo/glipizide group who entered Phase B were treated with blinded glipizide; the other subjects in the placebo/glipizide group were on insulin and per protocol did not receive blinded glipizide. The average daily dose of blinded glipizide was 3.85 mg/d. A subgroup analysis showed that treatment with omarigliptin led to reductions in HbA1c from baseline at Week 54 in all renal strata in subjects who were or were not on insulin at screening (Table S3 ).
The LS means and the 95% CIs for the change from baseline at 
| Safety results
| Phase A (24-week placebo-controlled period)
During the first 24 weeks (Phase A) of the trial, the incidences of subjects with one or more AEs, drug-related AEs, serious AEs (SAEs) and discontinuations due to AEs were similar in the omarigliptin and placebo groups ( 
T A B L E 2 Efficacy end-points at Week 24
were no clinically meaningful between-group differences in specific AEs in any System Organ Class (SOC, based on Medical Dictionary for Regulatory Activities Version 17.1 17 ; data not shown).
The percentage of subjects reporting one or more AEs of symptomatic hypoglycaemia was 17.0% (18/106) in the omarigliptin and 15.1% (16/106) in the placebo groups; P=0.709. All subjects experiencing an AE of symptomatic hypoglycaemia were on insulin therapy at screening ( Table 4 ). The incidences of severe hypoglycaemia (any episode of symptomatic hypoglycaemia that required medical or non-medical assistance) were 5.7% (6/106) in the omarigliptin and 7.5% (8/106) in the placebo groups; 1.9% of subjects (2/106) in the omarigliptin and 2.8% of subjects (3/106) in the placebo groups required medical assistance.
The LS mean (95% CI) change from baseline in eGFR was −0. 
| Phase A and Phase B (54-week treatment period)
Over the 54-week treatment period (Phase A and Phase B), there were no notable differences between the omarigliptin and placebo/ glipizide groups in summary AE measures, including the percentage of subjects with one or more AEs, drug-related AEs, SAEs, and discontinuations due to AEs (Table 3 ). There were no clinically meaningful differences in overall AEs by SOC or of any specific AE within an SOC (data not shown). In the renal disorders SOC, none of the AEs in the omarigliptin group led to the discontinuation of study medication or were considered by the investigator to be related to study drug.
The percentage of subjects reporting one or more AEs of symptomatic hypoglycaemia was 22.6% (24/106) in the omarigliptin and 20.8% (22/106) in the placebo/glipizide group; P=0.915. In those on insulin, the incidence of symptomatic hypoglycaemia was 32.9% in the omarigliptin group and 30.2% in the placebo/glipizide group (Table 4) .
One of the subjects with an AE of symptomatic hypoglycaemia in the omarigliptin group was not on insulin (2.8%), while three subjects not on insulin in the placebo/glipizide group had at least one AE of symptomatic hypoglycaemia (7.0%), one of which was severe.
The LS mean (95% CI) change from baseline in eGFR was −2. Small increases from baseline in mean serum amylase were observed in the overall population (combined strata) at Week 24 and Week 54 in both treatment groups; the mean change was slightly greater in the omarigliptin group at Week 24 but not at Week 54.
Mean baseline, Week 24 and Week 54 serum amylase levels were within normal laboratory range in both treatment groups (Table S4) . lipase were slightly above the laboratory upper limit of normal for both treatment groups (Table S4 ).
There were no adjudication-confirmed patients of prespecified hypersensitivity or pancreatitis (acute or chronic) during Phase A or Phase B of the trial.
| Population pharmacokinetics
Sparse PK data from this study were pooled with the PK data from other Phase 1, Phase 2 and Phase 3 trials for an integrated population PK analysis. The details of this analysis will be the subject of a separate publication. The population PK analysis, including PK data from this study, demonstrated that the 25 mg dose in subjects with moderate renal impairment and 12.5 mg dose in subjects with severe renal impairment and ESRD achieved omarigliptin plasma drug exposures which were within 1.5 -fold the exposure of 25 mg dose in a normal renal function. The results of the pooled PK analysis showed that plasma exposures with omarigliptin 12.5 mg and 25 mg were consistent with those predicted from an earlier clinical pharmacology trial. 18 
| DISCUSSION
Omarigliptin has a long half-life that supports once-weekly dosing.
The long half-life of omarigliptin is because of its limited metabolism and low renal clearance. Because omarigliptin is eliminated primarily T A B L E 3 Adverse events summary by the kidney, the assessment of efficacy and safety of omarigliptin in subjects with renal impairment is of particular interest.
In this study, in the overall population of subjects with renal impairment, treatment with omarigliptin once weekly for 24 weeks achieved a clinically meaningful reduction in HbA1c from baseline compared with placebo and the prespecified primary efficacy hypothesis for HbA1c in the placebo-controlled portion of the trial (Phase A) was met. The proportion of subjects achieving HbA1c goals of <7.0%
were numerically higher in the omarigliptin group than the placebo group, although the difference between the treatment groups was not significant. Treatment for 24 weeks with omarigliptin compared with placebo did not result in a significant reduction in FPG, the secondary glycaemic end-point. The lack of a between-group difference in FPG may be attributed to a decrease in FPG over 24 weeks observed in the placebo group. Notably, the initial (at Week 6) between-group difference in FPG was substantial, but subsequently FPG in the placebo group decreased from baseline, narrowing the difference between groups. The decrease in the placebo group was unexpected, and could reflect a trial effect in that group, with greater compliance to diet and medication (eg, insulin).
In subgroups based on degree of RI, similar reductions from baseline in HbA1c were observed across all renal strata in the omarigliptin group; however, because of varying degrees of reductions in HbA1c in the placebo group, smaller between-group differences in the severe RI and ESRD on dialysis subgroups were observed compared with the moderate RI subgroup. Subgroup results, which contain smaller numbers of subjects, should be viewed with caution since the study was not designed to have precision to examine subgroup effects.
Improvements in glycaemic control in subjects on placebo have been attributed to better adherence to diet and exercise associated with participation in a clinical trial, although this explanation is unlikely to completely account for the magnitude of effect observed in this study in some subgroups. Overall, 63% of subjects in the study were on insulin therapy. The change from baseline with placebo was more prominent in subjects on insulin than those not on insulin, which raises the possibility that the trial effect reflected not only better adherence to diet and exercise, but also better adherence to (or adjustment of) insulin therapy. Because subjects on insulin routinely monitor their finger-stick glucose, adherence to insulin, diet and exercise may be in- No notable between-group differences occurred in any SOC including the renal disorders SOC. Small mean decreases in eGFR were observed in both treatment groups. The percentage of subjects with worsening of renal function in both Phase A and B was similar between treatment groups. The small changes in these renal parameters are consistent with progression of renal disease that might be anticipated in the study population. 21 Thus, there were no findings to suggest that omarigliptin treatment increases the risk of worsening renal dysfunction in this study population with RI.
The hypoglycaemia profile is an important feature of any AHA. In this study, there were no notable between-group differences in the incidences of symptomatic, asymptomatic or severe hypoglycaemia.
Consistent with the recognised increase in hypoglycaemia when DPP-4 inhibitors are used with agents that are associated with hypoglycaemia (such as sulfonylureas and insulin) almost all of the subjects experiencing hypoglycaemia in this study were using insulin concomitantly, while only one subject in the omarigliptin group and three in the placebo/glipizide group not on insulin had an AE of symptomatic hypoglycaemia.
The small changes from baseline in mean serum amylase and lipase did not appear to be clinically meaningful. There were no patients of adjudication-confirmed pancreatitis in either treatment group.
The results of PK analysis were consistent with previous predictions that were used to support the selection of doses for this trial 18 
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